Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

235.04USD
22 May 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$235.04
Open
$231.92
Day's High
$236.89
Day's Low
$230.05
Volume
1,477,994
Avg. Vol
2,132,751
52-wk High
$388.67
52-wk Low
$216.12

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.96
Market Cap(Mil.): $45,161.65
Shares Outstanding(Mil.): 193.89
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 9.98 30.96 35.38
EPS (TTM): 23.33 -- --
ROI: 20.60 12.01 11.72
ROE: 33.64 13.30 16.38

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

May 14 2019

UPDATE 1-NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

May 14 2019

NHS England, Biogen reach deal on pricey drug for deadly disorder

NEW YORK, May 14 England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.

May 14 2019

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

Apr 25 2019

AbbVie says Humira rivals from Biogen, Amgen most aggressive so far

April 25 AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.

Apr 25 2019

Biogen dips as strategy post Alzheimer's setback fails to impress

Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.

Apr 24 2019

UPDATE 3-Biogen dips as strategy post Alzheimer's setback fails to impress

* Co beats 1st-qtr profit and revenue estimates (Adds details from conference call, analyst comment)

Apr 24 2019

Biogen first-quarter profit rises 20 percent

April 24 Drugmaker Biogen Inc reported a 20 percent rise in first-quarter profit on Wednesday on higher sales of its muscle disease treatment Spinraza.

Apr 24 2019

Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. group

ZURICH Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday.

Apr 03 2019

Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group

ZURICH, April 3 Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday.

Apr 03 2019

Earnings vs. Estimates